In this session, delve into the cutting-edge science of Molecular Residual Disease (MRD) testing, a revolutionary approach to cancer detection and treatment guidance. Leaders in the field will discuss the history of MRD – its foundations in clinical medicine – and where the opportunities exist for further research and application. We’ll explore how these tests can help determine prognosis/relapse risk, find early recurrence and individualize treatment to improve patient outcomes.

In this session, speakers will share best practices and key barriers in connecting patients to clinical trials following a cancer diagnosis. We will explore novel approaches to improve patient recruitment, retention and equitable access to clinical trials.

In this session, speakers will provide an update on the latest information related to young-onset breast and colorectal cancers, as well as current research, known risk factors and potential strategies to address this alarming trend.